Clinical Trials Directory

Trials / Completed

CompletedNCT06951282

Impact of Selenium on Methotrexate Induced Spermatotoxicity; A Comparative Study

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Ain Shams University · Academic / Other
Sex
Male
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

The aim of this study is to assess the potential protective role of selenium on semen parameters and its effect on seminal glutathione peroxidase level in patients on MTX therapy

Detailed description

The aim of this study is to assess the potential protective role of selenium on semen parameters and its effect on seminal glutathione peroxidase level in patients on MTX therapy. informed consent was obtained from each patient after explanation of the purpose of the study. All patients were subjected to history taking and general and local examination. Baseline semen analysis and seminal glutathione peroxidase (GPX) were done for all patients and then they were divided into four groups each has 10 patients. The no Se or MTX group was not eligible for neither Se nor MTX intake. The Se group started Se intake in a daily dose of 200 µg according to the United States National Academy of Sciences for 3 months. Patients of both MTX groups (MTX group \& MTX and Se group) were chosen from psoriatic patients already planned to start MTX treatment with subcutaneous dose of 0.3-0.4 mg/kg/week. The MTX and Se group started Se intake in a daily dose of 200 µg according to the United States National Academy of Sciences for 3 months. After 3 months, semen analysis and seminal GPX level were repeated.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTSelenium200 microgram selenium was given daily for 3 months
DRUGMethotrexate0.4 mg/kg/week sub cutaneous methotrexate for 3 months

Timeline

Start date
2024-05-02
Primary completion
2024-11-02
Completion
2024-12-31
First posted
2025-04-30
Last updated
2025-04-30

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06951282. Inclusion in this directory is not an endorsement.